Substance / Medication

Lofexidine

Overview

Active Ingredient
lofexidine
RxNorm CUI
28863

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

3 trials linked to this intervention

3
Total Trials
0
Recruiting
1
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Effect of lofexidine on cardiac repolarization during treatment of opioid withdrawal.
Darpö Börje, Pirner Mark, Longstreth James et al. · Drug Alcohol Depend · 2019
PMID: 31606589RCTFull text (PMC)
Dronabinol and lofexidine for cannabis use disorder: A randomized, double-blind, placebo-controlled trial.
Levin Frances R, Mariani John J, Pavlicova Martina et al. · Drug Alcohol Depend · 2016
PMID: 26711160RCTFull text (PMC)
Assessment of safety, cardiovascular and subjective effects after intravenous cocaine and lofexidine.
De La Garza R, Galloway G P, Newton T F et al. · Prog Neuropsychopharmacol Biol Psychiatry · 2014
PMID: 24316175RCTFull text (PMC)
Effects of lofexidine on stress-induced and cue-induced opioid craving and opioid abstinence rates: preliminary findings.
Sinha Rajita, Kimmerling Anne, Doebrick Cheryl et al. · Psychopharmacology (Berl) · 2007
PMID: 17136399RCT
Lofexidine versus diazepam for the treatment of opioid withdrawal syndrome: A double-blind randomized clinical trial in Singapore.
Guo Song, Manning Victoria, Yang Yi et al. · J Subst Abuse Treat · 2018
PMID: 29910009Observational
Pharmacokinetics of lofexidine hydrochloride in healthy volunteers.
Al-Ghananeem Abeer M · J Pharm Sci · 2009
PMID: 18393298Observational
Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse.
Haney Margaret, Hart Carl L, Vosburg Suzanne K et al. · Psychopharmacology (Berl) · 2008
PMID: 18161012ObservationalFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Lofexidine (substance)
SNOMED CT
395989000
UMLS CUI
C0065152
RxNorm CUI
28863

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
3
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.